{"analyses":[{"ciLowerLimit":"-5.34","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.951","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"1.605","estimateComment":"The treatment was considered efficacious if the group by time interaction for LVESV was statistically significant at a two-sided p\\<0.05 and the expected LVESV was lower for carvedilol than placebo over time.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.17","paramType":"Slope","paramValue":"-2.194","statisticalComment":"The treatment effect was determined by testing the significance of the group by time interaction in GEE using a one degree-of-freedom (df) test.","statisticalMethod":"Generalized Estimating Equation (GEE)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.3907","value":"42.2193"},{"groupId":"OG001","spread":"1.3633","value":"39.7354"}]}],"title":"BL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.4041","value":"41.6128"},{"groupId":"OG001","spread":"1.5337","value":"41.3839"}]}],"title":"6m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.3498","value":"42.8437"},{"groupId":"OG001","spread":"1.6275","value":"41.8113"}]}],"title":"12m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.605","value":"43.1453"},{"groupId":"OG001","spread":"2.1281","value":"42.5634"}]}],"title":"18m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.7268","value":"42.0086"},{"groupId":"OG001","spread":"2.3661","value":"42.442"}]}],"title":"24m"}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"description":"The amount of blood (in ml) in the heart's left ventricle just after the heart contracts. The mean is reported by arm at each timepoint with corresponding standard errors.","dispersionType":"Standard Error","groups":[{"description":"Patients received Carvedilol PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.","id":"OG000","title":"Arm I (Carvedilol)"},{"description":"Patients received Placebo PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.","id":"OG001","title":"Arm II (Placebo)"}],"paramType":"MEAN","populationDescription":"We excluded 31 participants who did not have a second time point assessment of echocardiography, resulting in 151 analyzable participants.","reportingStatus":"POSTED","timeFrame":"Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation","title":"Average Left Ventricular End-systolic Volume","type":"SECONDARY","unitOfMeasure":"ml"}